23 / 36
Toxicity with enzalutamide in patients aged <75 years and ≥75 years
Parameter
Enzalutamide
Placebo
Patients aged <75 years
(n=554)
Patients aged ≥75 years
(n=317)
Patients aged <75 years
(n=554)
Patients aged ≥75 years
(n=292)
AE, n (%)
Any AE
530 (95.7)
314 (99.1)
510 (92.4)
277 (94.9)
Any Grade ≥3 AE
219 (39.5)
155 (48.9)
191 (34.6)
122 (41.8)
Any serious AE
156 (28.2)
123 (38.8)
130 (23.6)
96 (32.9)
Most common AEs (any grade)
Fatigue
191 (34.5)
119 (37.5)
142 (25.7)
76 (26.0)
Back pain
148 (26.7)
87 (27.4)
131 (23.7)
56 (19.2)
Constipation
118 (21.3)
75 (23.7)
94 (17.0)
51 (17.5)
Arthralgia
115 (20.8)
62 (19.6)
96 (17.4)
39 (13.4)
Decreased appetite
88 (15.9)
70 (22.1)
81 (14.7)
55 (18.8)
AEs occurring in ≥20% patients
Graff JN,
et al. Ann Oncol
2016;27:286–94.
Age and clinical outcome with
enzalutamide